Global Contraceptives Market: Drivers, Opportunities, Trends and Forecast 2017-2023
Global Contraceptives Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Birth control has a broad positive impact and has expanded opportunities for women in terms of economic advancements, educational attainment, and improved health outcomes. A contraceptive helps individuals and couples to gain basic right and is a right to decide when and how many children to have. The rising adoption of traditional and modern methods of contraception has resulted in the improvement not only in health-related outcomes but in several economic and social issues. For instance, it has reduced the infant mortality and maternal mortality rates. According to Centers for Disease Control and Prevention (CDC), the introduction toward access to modern contraceptives is among one of the 10 great public health achievements of the 20th century.
The implementation of modern contraceptive methods offers safe provision by eliminating unwanted restrictive practices and medical barriers. The WHO has developed a set of medical eligibility criteria that is based on a collaborative review of all clinical, research, epidemiological, and modern contraceptive methods.
The major products in the market include:
Market Analysis: The Global Contraceptives Market is estimated to witness a CAGR of 4.3% during the forecast period 2017–2023. The market is analyzed based on three segments, namely product type, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the contraceptives market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to the highest proportion of young women who need to use modern contraceptives methods. Further, the government is focusing toward improvising healthcare infrastructure and creating awareness among people for early prevention of unintended pregnancies. However, the healthcare expenditure in most of the developing countries have saved millions of dollars by adopting contraceptives, especially oral pills.
The government in most of the developing countries are taking initiatives for creating awareness about contraceptives by conducting programs and collaborating with NGOs to have an effective spread of contraceptives in order to reduce poverty and illiteracy caused due to unplanned births. It is encouraging the use of condoms by supplying them door to door and imparting knowledge to prevent the spread of STDs and restrict population growth. However, few rural areas, and cultural and religious opposition in certain emerging countries, such as China, India, Thailand, Vietnam, Malaysia, and Philippines, hinder the market growth.
Product Analysis: Contraceptive drugs are growing at a moderate rate and dominates the global contraceptives market with 62% of the total market share. Factors, such as rise in prevalence of unwanted pregnancies, rise in adoption of oral pills and its advantages over other contraceptives, and government initiatives, are driving the market growth. Contraceptive drugs are most frequently used for birth control and is widely adopted among young couples and career-oriented professional women. Contraceptive devices play an important role in saving individuals from getting STDs, preventing unwanted pregnancies, and help in family planning. The contraceptive devices market is estimated to be $10.5 billion in 2016 and is expected to reach $15.6 billion by 2023, growing at a CAGR of 5.7% during the forecast period, 2016-2023.
Key Players: Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.
Competitive Analysis: The global contraceptives market has immense growth opportunities for vendors in both developed and developing regions. The market in the developed countries is seeing an increase in the adoption of modern contraceptives, especially in the US, Canada, France, Germany, the UK, and few of the Middle East countries. These countries have the highest number of frequent user population accounting to 70% to 75% of the total contraceptive population worldwide.
Pharmaceutical companies are the leading vendors in the market and have major competition with other vendors for the use of contraceptives. The market has substantial potential to gain attention of several new vendors in developing countries, thereby intensifying the competition. The vendors have strong focus on understanding the customer base by creating awareness and initiatives to generate knowledge about their products and upcoming technologically-advanced contraceptives. The growing awareness about the products and a rise in the number of physician-owned implant distributions that have resulted in an increase in the volume of contraceptive procedures have led individuals undergo implantation of contraceptive devices.
Benefits: The report provides complete details about the usage and adoption rate of contraceptives for birth control, family planning, and to avoid unwanted pregnancies. Therefore, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward contraceptive adoption in the upcoming years. They can also get details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Birth control has a broad positive impact and has expanded opportunities for women in terms of economic advancements, educational attainment, and improved health outcomes. A contraceptive helps individuals and couples to gain basic right and is a right to decide when and how many children to have. The rising adoption of traditional and modern methods of contraception has resulted in the improvement not only in health-related outcomes but in several economic and social issues. For instance, it has reduced the infant mortality and maternal mortality rates. According to Centers for Disease Control and Prevention (CDC), the introduction toward access to modern contraceptives is among one of the 10 great public health achievements of the 20th century.
The implementation of modern contraceptive methods offers safe provision by eliminating unwanted restrictive practices and medical barriers. The WHO has developed a set of medical eligibility criteria that is based on a collaborative review of all clinical, research, epidemiological, and modern contraceptive methods.
The major products in the market include:
- Yasmin and Yaz (oral pills)
- NuvaRing (Vaginal Ring)
- Milex Wide Seal (Diaphragm)
- Mirena and ParaGard (IUDs)
- Ortho Evra (or Evra patch)
- Implanon (implant)
Market Analysis: The Global Contraceptives Market is estimated to witness a CAGR of 4.3% during the forecast period 2017–2023. The market is analyzed based on three segments, namely product type, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the contraceptives market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to the highest proportion of young women who need to use modern contraceptives methods. Further, the government is focusing toward improvising healthcare infrastructure and creating awareness among people for early prevention of unintended pregnancies. However, the healthcare expenditure in most of the developing countries have saved millions of dollars by adopting contraceptives, especially oral pills.
The government in most of the developing countries are taking initiatives for creating awareness about contraceptives by conducting programs and collaborating with NGOs to have an effective spread of contraceptives in order to reduce poverty and illiteracy caused due to unplanned births. It is encouraging the use of condoms by supplying them door to door and imparting knowledge to prevent the spread of STDs and restrict population growth. However, few rural areas, and cultural and religious opposition in certain emerging countries, such as China, India, Thailand, Vietnam, Malaysia, and Philippines, hinder the market growth.
Product Analysis: Contraceptive drugs are growing at a moderate rate and dominates the global contraceptives market with 62% of the total market share. Factors, such as rise in prevalence of unwanted pregnancies, rise in adoption of oral pills and its advantages over other contraceptives, and government initiatives, are driving the market growth. Contraceptive drugs are most frequently used for birth control and is widely adopted among young couples and career-oriented professional women. Contraceptive devices play an important role in saving individuals from getting STDs, preventing unwanted pregnancies, and help in family planning. The contraceptive devices market is estimated to be $10.5 billion in 2016 and is expected to reach $15.6 billion by 2023, growing at a CAGR of 5.7% during the forecast period, 2016-2023.
Key Players: Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.
Competitive Analysis: The global contraceptives market has immense growth opportunities for vendors in both developed and developing regions. The market in the developed countries is seeing an increase in the adoption of modern contraceptives, especially in the US, Canada, France, Germany, the UK, and few of the Middle East countries. These countries have the highest number of frequent user population accounting to 70% to 75% of the total contraceptive population worldwide.
Pharmaceutical companies are the leading vendors in the market and have major competition with other vendors for the use of contraceptives. The market has substantial potential to gain attention of several new vendors in developing countries, thereby intensifying the competition. The vendors have strong focus on understanding the customer base by creating awareness and initiatives to generate knowledge about their products and upcoming technologically-advanced contraceptives. The growing awareness about the products and a rise in the number of physician-owned implant distributions that have resulted in an increase in the volume of contraceptive procedures have led individuals undergo implantation of contraceptive devices.
Benefits: The report provides complete details about the usage and adoption rate of contraceptives for birth control, family planning, and to avoid unwanted pregnancies. Therefore, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward contraceptive adoption in the upcoming years. They can also get details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
4 MARKET OUTLOOK
4.1 Overview
4.2 Porter 5 (Five) Forces
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Growing incidence of unwanted pregnancies
4.4.1.2 Increase in prevalence of contraception
4.4.1.3 Rise in adoption of oral pills and its advantages over other contraceptives
4.4.1.4 Government initiatives
4.4.1.5 Unmet need for contraception in developing countries
4.4.2 Restraints
4.4.2.1 Prolonged regulatory approvals of contraceptives
4.4.2.2 Cultural and religious opposition
4.4.2.1 Availability of low cost generic contraceptives
4.4.2.2 Limited knowledge about modern contraceptives
4.4.2.3 Intense competition among vendors
4.4.3 Opportunities
4.4.3.1 Technological advancements
4.4.3.2 Rise in effective awareness programs
4.4.3.3 High demand of cheap contraceptives
4.4.3.4 Increase in mergers and acquisition
4.4.3.5 Increase in healthcare spending
4.4.4 DRO – Impact Analysis
4.4.5 Key Stakeholders
5 MARKET SEGMENTATION BY PRODUCT TYPES: MARKET SIZE & ANALYSIS
5.1 Overview
5.1.1 Market Size and Analysis
5.2 Contraceptive Drugs Market
5.3 Contraceptive Devices Market
5.4 Global Condom Market
5.4.1 Global IUD Market
5.4.1.1 Overview
5.4.2 Global sub-dermal Implants
5.4.2.1 Overview
5.4.3 Global Vaginal Rings Market
5.4.3.1 Overview
5.4.4 Global Non-Surgical Permanent Contraceptive Market
5.4.4.1 Overview
5.4.5 Global Diaphragms Market
5.4.5.1 Overview
5.4.6 Global Sponges Market
5.4.6.1 Overview
6 REGIONS: MARKET SIZE & ANALYSIS
6.1 North America
6.1.1 Market Overview
6.2 Europe
6.2.1 Market Overview
6.3 APAC
6.3.1 Market Overview
6.4 Rest of the World
6.4.1 Market Overview
7 COMPETITIVE LANDSCAPE
7.1 Competitor Comparison Analysis
8 VENDOR PROFILES
8.1.1 Allergan plc
8.1.1.1 Overview
8.1.1.2 Business unit
8.1.1.3 Business focus
8.1.1.4 SWOT analysis
8.1.1.5 Business strategies
8.1.2 Bayer AG
8.1.2.1 Overview
8.1.2.2 Business unit
8.1.2.3 Business focus
8.1.2.4 SWOT analysis
8.1.2.5 Business strategies
8.1.3 Merck & Co., Inc.
8.1.3.1 Overview
8.1.3.2 Business unit
8.1.3.3 Business focus
8.1.3.4 SWOT analysis
8.1.3.5 Business strategies
8.1.4 Teva Pharmaceutical Industries Ltd
8.1.4.1 Overview
8.1.4.2 Business unit
8.1.4.3 Business focus
8.1.4.4 SWOT analysis
8.1.4.5 Business strategies
8.1.5 Church & Dwight
8.1.5.1 Overview
8.1.5.2 Business unit
8.1.5.3 Business focus
8.1.5.4 SWOT analysis
8.1.5.5 Business strategies
Annexure
? Acronyms
Table 1 CONTRACEPTIVE MARKET REVENUE BY TYPE, 2016-2023 ($BILLION)
Table 2 GLOBAL CONTRACEPTIVES MARKET REVENUE BY REGIONS FORECAST, 2016–2023 ($MILLION)
Table 3 DRO (NORTH AMERICA)
Table 4 DRO (EUROPE)
Table 5 DRO (APAC)
Table 6 DRO (REST OF THE WORLD)
Table 1 ALLERGAN PLC: PRODUCT OFFERINGS
Table 2 ALLERGAN PLC: RECENT DEVELOPMENTS
Table 3 BAYER AG: PRODUCT OFFERINGS
Table 4 BAYER AG: RECENT DEVELOPMENTS
Table 5 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERINGS
Table 6 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS
Table 7 MERCK & CO: PRODUCT OFFERINGS
Table 8 MERCK & CO: RECENT DEVELOPMENTS
Table 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS
Table 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS
Charts
Chart 1 CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS
Chart 2 PERCENTAGE OF ADOLESCENCE WOMEN AT EACH AGE GROUP IN ALL DEVELOPING REGIONS 2016
Chart 3 PERCENTAGE SPLIT OF 252 MILLION WOMEN AGED 15-19 YEARS, 2016
Chart 4 PERCENTAGE OF MODERN CONTRACEPTION METHODS USAGE AMONG WOMEN AGED 15 TO 49 YEARS (MARRIED OR IN A UNION), 2015
Chart 5 NUMBER OF MARRIED OR IN UNION WOMEN USING CONTRACEPTION (MILLIONS), IN 2015
Chart 6 DEVELOPMENTS IN CONTRACEPTIVE METHODS
Chart 8 RESEARCH METHODOLOGY
Chart 9 GLOBAL MEDICAL INDUSTRY SEGMENTATION
Chart 10 MEDICAL ELIGIBILITY BY CATEGORIES
Chart 11 GLOBAL CONTRACEPTIVES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 12 PORTERS 5 FORCES ON CONTRACEPTIVES MARKET
Chart 13 CONTRACEPTIVES MARKET SEGMENTATION
Chart 14 MARKET DYNAMICS – DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Chart 15 GLOBAL CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS, 2015
Chart 16 THE PERCENTAGE OF THOSE WHO LIMIT BIRTH IS TWICE AS HIGH IN SOUTH CENTRAL ASIA AND SOUTHEAST ASIA WHEN COMPARED TO THOSE WOMEN IN SUB-SAHARAN AFRICA.
Chart 17 DRO - IMPACT ANALYSIS OF IOT HEALTHCARE MARKET
Chart 18 KEY STAKEHOLDERS
Chart 19 CONTRACEPTIVES MARKET SEGMENTATION BY PRODUCT TYPE, 2016
Chart 20 CONTRACEPTIVES MARKET REVENUE BY TYPE, 2016-2023 ($MILLION)
Chart 21 PERCENTAGE SPLIT OF CONTRACEPTIVE MARKET 2016
Chart 22 CONTRACEPTIVE DRUGS MARKET SEGMENTATION 2016
Chart 23 CONTRACEPTIVES DRUGS MARKET REVENUE, 2016-2023
Chart 24 CONTRACEPTIVE DEVICES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 25 CONTACEPTIVE DEVICES MARKET SEGMENTATTION 2016
Chart 26 CONTRACEPTIVE DEVICES SEGMENTATION 2016 (% SHARE)
Chart 27 GLOBAL CONDOM MARKET REVENUE, 2016-2023 ($MILLION)
Chart 28 GLOBAL IUD MARKET REVENUE, 2016-2023 ($MILLION)
Chart 29 GLOBAL SUB-DERMAL IMPLANTS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 30 GLOBAL VAGINAL RINGS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 31 GLOBAL NON-SURGICAL PERMANENT CONTRACEPTIVE MARKET REVENUE, 2016-2023 ($MILLION)
Chart 32 GLOBAL DIAPHRAGMS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 33 GLOBAL SPONGES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 34 GLOBAL CONTRACEPTIVES MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 AND 2023 (% SHARE)
Chart 35 GLOBAL CONTRACEPTIVES MARKET OVERVIEW BY REGIONS 2016 ($ MILLION)
Chart 36 CONTRACEPTIVES MARKET REVENUE IN NORTH AMERICA, 2016–2023 ($MILLION)
Chart 37 CONTRACEPTIVES MARKET REVENUE IN THE EUROPE, 2016–2023 ($MILLION)
Chart 38 CONTRACEPTIVES MARKET REVENUE IN APAC, 2016–2023 ($MILLION)
Chart 39 CONTRACEPTIVES MARKET REVENUE IN THE REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 40 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 ($MILLION)
Chart 41 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (% SHARE)
Chart 42 ALLERGAN PLC: OVERVIEW SNAPSHOT
Chart 43 ALLERGAN PLC: BUSINESS UNITS
Chart 44 ALLERGAN PLC: SWOT ANALYSIS
Chart 45 BAYER AG: OVERVIEW SNAPSHOT
Chart 46 BAYER AG: BUSINESS UNITS
Chart 47 BAYER AG: SWOT ANALYSIS
Chart 48 CHURCH & DWIGHT CO., INC.: OVERVIEW SNAPSHOT
Chart 49 CHURCH & DWIGHT CO., INC.: BUSINESS UNITS
Chart 50 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS
Chart 51 MERCK & CO: OVERVIEW SNAPSHOT
Chart 52 MERCK & CO: BUSINESS UNITS
Chart 53 MERCK & CO: SWOT ANALYSIS
Chart 54 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT
Chart 55 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS
Chart 56 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
1.1 Industry Overview
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
4 MARKET OUTLOOK
4.1 Overview
4.2 Porter 5 (Five) Forces
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Growing incidence of unwanted pregnancies
4.4.1.2 Increase in prevalence of contraception
4.4.1.3 Rise in adoption of oral pills and its advantages over other contraceptives
4.4.1.4 Government initiatives
4.4.1.5 Unmet need for contraception in developing countries
4.4.2 Restraints
4.4.2.1 Prolonged regulatory approvals of contraceptives
4.4.2.2 Cultural and religious opposition
4.4.2.1 Availability of low cost generic contraceptives
4.4.2.2 Limited knowledge about modern contraceptives
4.4.2.3 Intense competition among vendors
4.4.3 Opportunities
4.4.3.1 Technological advancements
4.4.3.2 Rise in effective awareness programs
4.4.3.3 High demand of cheap contraceptives
4.4.3.4 Increase in mergers and acquisition
4.4.3.5 Increase in healthcare spending
4.4.4 DRO – Impact Analysis
4.4.5 Key Stakeholders
5 MARKET SEGMENTATION BY PRODUCT TYPES: MARKET SIZE & ANALYSIS
5.1 Overview
5.1.1 Market Size and Analysis
5.2 Contraceptive Drugs Market
5.3 Contraceptive Devices Market
5.4 Global Condom Market
5.4.1 Global IUD Market
5.4.1.1 Overview
5.4.2 Global sub-dermal Implants
5.4.2.1 Overview
5.4.3 Global Vaginal Rings Market
5.4.3.1 Overview
5.4.4 Global Non-Surgical Permanent Contraceptive Market
5.4.4.1 Overview
5.4.5 Global Diaphragms Market
5.4.5.1 Overview
5.4.6 Global Sponges Market
5.4.6.1 Overview
6 REGIONS: MARKET SIZE & ANALYSIS
6.1 North America
6.1.1 Market Overview
6.2 Europe
6.2.1 Market Overview
6.3 APAC
6.3.1 Market Overview
6.4 Rest of the World
6.4.1 Market Overview
7 COMPETITIVE LANDSCAPE
7.1 Competitor Comparison Analysis
8 VENDOR PROFILES
8.1.1 Allergan plc
8.1.1.1 Overview
8.1.1.2 Business unit
8.1.1.3 Business focus
8.1.1.4 SWOT analysis
8.1.1.5 Business strategies
8.1.2 Bayer AG
8.1.2.1 Overview
8.1.2.2 Business unit
8.1.2.3 Business focus
8.1.2.4 SWOT analysis
8.1.2.5 Business strategies
8.1.3 Merck & Co., Inc.
8.1.3.1 Overview
8.1.3.2 Business unit
8.1.3.3 Business focus
8.1.3.4 SWOT analysis
8.1.3.5 Business strategies
8.1.4 Teva Pharmaceutical Industries Ltd
8.1.4.1 Overview
8.1.4.2 Business unit
8.1.4.3 Business focus
8.1.4.4 SWOT analysis
8.1.4.5 Business strategies
8.1.5 Church & Dwight
8.1.5.1 Overview
8.1.5.2 Business unit
8.1.5.3 Business focus
8.1.5.4 SWOT analysis
8.1.5.5 Business strategies
Annexure
? Acronyms
Table 1 CONTRACEPTIVE MARKET REVENUE BY TYPE, 2016-2023 ($BILLION)
Table 2 GLOBAL CONTRACEPTIVES MARKET REVENUE BY REGIONS FORECAST, 2016–2023 ($MILLION)
Table 3 DRO (NORTH AMERICA)
Table 4 DRO (EUROPE)
Table 5 DRO (APAC)
Table 6 DRO (REST OF THE WORLD)
Table 1 ALLERGAN PLC: PRODUCT OFFERINGS
Table 2 ALLERGAN PLC: RECENT DEVELOPMENTS
Table 3 BAYER AG: PRODUCT OFFERINGS
Table 4 BAYER AG: RECENT DEVELOPMENTS
Table 5 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERINGS
Table 6 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS
Table 7 MERCK & CO: PRODUCT OFFERINGS
Table 8 MERCK & CO: RECENT DEVELOPMENTS
Table 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS
Table 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS
Charts
Chart 1 CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS
Chart 2 PERCENTAGE OF ADOLESCENCE WOMEN AT EACH AGE GROUP IN ALL DEVELOPING REGIONS 2016
Chart 3 PERCENTAGE SPLIT OF 252 MILLION WOMEN AGED 15-19 YEARS, 2016
Chart 4 PERCENTAGE OF MODERN CONTRACEPTION METHODS USAGE AMONG WOMEN AGED 15 TO 49 YEARS (MARRIED OR IN A UNION), 2015
Chart 5 NUMBER OF MARRIED OR IN UNION WOMEN USING CONTRACEPTION (MILLIONS), IN 2015
Chart 6 DEVELOPMENTS IN CONTRACEPTIVE METHODS
Chart 8 RESEARCH METHODOLOGY
Chart 9 GLOBAL MEDICAL INDUSTRY SEGMENTATION
Chart 10 MEDICAL ELIGIBILITY BY CATEGORIES
Chart 11 GLOBAL CONTRACEPTIVES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 12 PORTERS 5 FORCES ON CONTRACEPTIVES MARKET
Chart 13 CONTRACEPTIVES MARKET SEGMENTATION
Chart 14 MARKET DYNAMICS – DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Chart 15 GLOBAL CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS, 2015
Chart 16 THE PERCENTAGE OF THOSE WHO LIMIT BIRTH IS TWICE AS HIGH IN SOUTH CENTRAL ASIA AND SOUTHEAST ASIA WHEN COMPARED TO THOSE WOMEN IN SUB-SAHARAN AFRICA.
Chart 17 DRO - IMPACT ANALYSIS OF IOT HEALTHCARE MARKET
Chart 18 KEY STAKEHOLDERS
Chart 19 CONTRACEPTIVES MARKET SEGMENTATION BY PRODUCT TYPE, 2016
Chart 20 CONTRACEPTIVES MARKET REVENUE BY TYPE, 2016-2023 ($MILLION)
Chart 21 PERCENTAGE SPLIT OF CONTRACEPTIVE MARKET 2016
Chart 22 CONTRACEPTIVE DRUGS MARKET SEGMENTATION 2016
Chart 23 CONTRACEPTIVES DRUGS MARKET REVENUE, 2016-2023
Chart 24 CONTRACEPTIVE DEVICES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 25 CONTACEPTIVE DEVICES MARKET SEGMENTATTION 2016
Chart 26 CONTRACEPTIVE DEVICES SEGMENTATION 2016 (% SHARE)
Chart 27 GLOBAL CONDOM MARKET REVENUE, 2016-2023 ($MILLION)
Chart 28 GLOBAL IUD MARKET REVENUE, 2016-2023 ($MILLION)
Chart 29 GLOBAL SUB-DERMAL IMPLANTS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 30 GLOBAL VAGINAL RINGS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 31 GLOBAL NON-SURGICAL PERMANENT CONTRACEPTIVE MARKET REVENUE, 2016-2023 ($MILLION)
Chart 32 GLOBAL DIAPHRAGMS MARKET REVENUE, 2016-2023 ($MILLION)
Chart 33 GLOBAL SPONGES MARKET REVENUE, 2016-2023 ($MILLION)
Chart 34 GLOBAL CONTRACEPTIVES MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 AND 2023 (% SHARE)
Chart 35 GLOBAL CONTRACEPTIVES MARKET OVERVIEW BY REGIONS 2016 ($ MILLION)
Chart 36 CONTRACEPTIVES MARKET REVENUE IN NORTH AMERICA, 2016–2023 ($MILLION)
Chart 37 CONTRACEPTIVES MARKET REVENUE IN THE EUROPE, 2016–2023 ($MILLION)
Chart 38 CONTRACEPTIVES MARKET REVENUE IN APAC, 2016–2023 ($MILLION)
Chart 39 CONTRACEPTIVES MARKET REVENUE IN THE REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 40 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 ($MILLION)
Chart 41 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (% SHARE)
Chart 42 ALLERGAN PLC: OVERVIEW SNAPSHOT
Chart 43 ALLERGAN PLC: BUSINESS UNITS
Chart 44 ALLERGAN PLC: SWOT ANALYSIS
Chart 45 BAYER AG: OVERVIEW SNAPSHOT
Chart 46 BAYER AG: BUSINESS UNITS
Chart 47 BAYER AG: SWOT ANALYSIS
Chart 48 CHURCH & DWIGHT CO., INC.: OVERVIEW SNAPSHOT
Chart 49 CHURCH & DWIGHT CO., INC.: BUSINESS UNITS
Chart 50 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS
Chart 51 MERCK & CO: OVERVIEW SNAPSHOT
Chart 52 MERCK & CO: BUSINESS UNITS
Chart 53 MERCK & CO: SWOT ANALYSIS
Chart 54 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT
Chart 55 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS
Chart 56 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
